Evidence map›Paper›PMID 35083194›Full record

ReviewFrontiers in chemistry2021

The Potential of Modified and Multimeric Antimicrobial Peptide Materials as Superbug Killers.

Tamara Matthyssen, Wenyi Li, James A Holden, Jason C Lenzo, Sara Hadjigol, Neil M O'Brien-Simpson

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tamara MatthyssenACTV Research Group, The University of Melbourne, Melbourne Dental School, Centre for Oral Health Research, Royal Dental Hospital, Melbourne, VIC, Australia.
Wenyi LiACTV Research Group, The University of Melbourne, Melbourne Dental School, Centre for Oral Health Research, Royal Dental Hospital, Melbourne, VIC, Australia.
James A HoldenCentre for Oral Health Research, The University of Melbourne, Melbourne Dental School, Royal Dental Hospital, Melbourne, VIC, Australia.
Jason C LenzoCentre for Oral Health Research, The University of Melbourne, Melbourne Dental School, Royal Dental Hospital, Melbourne, VIC, Australia.
Sara HadjigolACTV Research Group, The University of Melbourne, Melbourne Dental School, Centre for Oral Health Research, Royal Dental Hospital, Melbourne, VIC, Australia.
Neil M O'Brien-SimpsonACTV Research Group, The University of Melbourne, Melbourne Dental School, Centre for Oral Health Research, Royal Dental Hospital, Melbourne, VIC, Australia.
Royal Dental Hospital of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are found in nearly all living organisms, show broad spectrum antibacterial activity, and can modulate the immune system. Furthermore, they have a very low level of resistance induction in bacteria, which makes them an ideal target for drug development and for targeting multi-drug resistant bacteria 'Superbugs'. Despite this promise, AMP therapeutic use is hampered as typically they are toxic to mammalian cells, less active under physiological conditions and are susceptible to proteolytic degradation. Research has focused on addressing these limitations by modifying natural AMP sequences by including e.g., d-amino acids and N-terminal and amino acid side chain modifications to alter structure, hydrophobicity, amphipathicity, and charge of the AMP to improve antimicrobial activity and specificity and at the same time reduce mammalian cell toxicity. Recently, multimerisation (dimers, oligomer conjugates, dendrimers, polymers and self-assembly) of natural and modified AMPs has further been used to address these limitations and has created compounds that have improved activity and biocompatibility compared to their linear counterparts. This review investigates how modifying and multimerising AMPs impacts their activity against bacteria in planktonic and biofilm states of growth.

Indexed as

AMPs5antimicrobials1multimerisation3peptides2superbugs4

Identifiers

PMID35083194
PMCPMC8785218
OpenAlexW4205979191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.